Advertisement

Preoperative Chemo- and Endocrine Therapy

  • Rosalba Torrisi
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

Primary systemic therapy (PST) or preoperative therapy has been part of the multidisciplinary approach to locally advanced and inflammatory breast cancer since the early 1970s. The administration of chemotherapy allowed surgical resection of inoperable tumours and improved clinical outcome [1]. The chance of downsizing the tumour extended its use to operable large breast tumour candidates for mastectomy in order to reduce the extent of surgery. A series of phase II trials reporting an objective response rate ranging from 60 to 90%, showed the feasibility of this approach in terms of significant activity with no detriment to survival [2]. In addition, the early administration of medical treatment appeared an attractive means to improve clinical outcome.

Keywords

Inflammatory Breast Cancer Hormone Receptor Status HER2 Positive Breast Cancer Recurrence Score Clinical Response Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Giordano SH. Update on locally advanced breast cancer. The Oncologist. 2003;8:521–530.PubMedCrossRefGoogle Scholar
  2. 2.
    Wolff AC and Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol. 2000;18:1558–69.PubMedGoogle Scholar
  3. 3.
    Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumour removal and chemotherapy on kinetics and growth of metastasis. Cancer Res. 1983;43:1488–92.PubMedGoogle Scholar
  4. 4.
    Mauriac L, Mc Grogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm : A unicentre randomized trial with a 124-month median follow-up. Institute Bergonie Bordeaux Group Seine (IBBGS). Ann Oncol. 1999;10:47–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Semiglazov VF, TopuzovEE, Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primay radiotherapy alone in stage IIb–IIIa breast cancer. Ann Oncol. 1994;5:591–95.PubMedGoogle Scholar
  6. 6.
    Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant vs adjuvant chemotherapy in premnopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomized trial. Eur J Cancer. 1994;30A:645–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.PubMedGoogle Scholar
  8. 8.
    Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. An Oncol. 1998;9:1179–84.CrossRefGoogle Scholar
  9. 9.
    Jakesz R, for the ABCSG. Comparison of pre- of postoperative chemotherapy in breast cancer patients. Four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG ) trial 7. Proc Am Soc Clin Oncol. 2001;20:125Google Scholar
  10. 10.
    Van der Hage JA, van der Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–37.PubMedGoogle Scholar
  11. 11.
    Bear HD, Anderson S, Brown A, et al. The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–27.PubMedCrossRefGoogle Scholar
  13. 13.
    Gianni L, Baselga J, Eiermann V, et al. European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide, methotrexate and fluorouracile (CMF). Proc Am Soc Clin Oncol. 2005;24:513.Google Scholar
  14. 14.
    Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst. 2005;97(3)188–94.Google Scholar
  15. 15.
    Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer. Nine-year results from National Surgical adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.PubMedCrossRefGoogle Scholar
  16. 16.
    Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91:2012–17.PubMedCrossRefGoogle Scholar
  17. 17.
    Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res. 2004;10:6622–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumour response as preoperative therapy. Clin Cancer Res. 2005;11:8715–8721.PubMedCrossRefGoogle Scholar
  20. 20.
    Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol. 2006;24:1940–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Sachelarie I, GRossband ML, Chadha M, et al. Primary systemic therapy of breast cancer. The Oncologist. 2006;11:574–89.PubMedCrossRefGoogle Scholar
  22. 22.
    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–69.PubMedGoogle Scholar
  23. 23.
    Hennessy BT, Hortobagyi GN, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304–11.PubMedCrossRefGoogle Scholar
  24. 24.
    Mazouni CX, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adverse patient outcome. J Clin Oncol. 2007;25:2650–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: Practicalities and applications. Breast Cancer Res. 2006;8:216 (doid:10.1186/bcr1618).PubMedCrossRefGoogle Scholar
  26. 26.
    Chang J, Powles T, Allred D, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999;17:3058–63.PubMedGoogle Scholar
  27. 27.
    Burcombe RJ, Makris A, Richman PI, et al. Evaluation of ER, PgR, HER2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92:147–55.PubMedCrossRefGoogle Scholar
  28. 28.
    Dowsett M, Ebbs SR, Dixon M, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER2 in breast cancer – a study from the IMPACT trialists. J Clin Oncol. 2005;23:2477–92.PubMedCrossRefGoogle Scholar
  29. 29.
    Untch M, Konecny G, Ditsch N, et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomized AGO study. Proc Am Soc Clin Oncol. 2002;21:133a.Google Scholar
  30. 30.
    Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–85.CrossRefGoogle Scholar
  31. 31.
    Von Minckwitz G, Blohmer J-U, Raab G et al. In vivo chemosensitivity – adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 2005;16:56–63.CrossRefGoogle Scholar
  32. 32.
    Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol. 2007;23:41–48.CrossRefGoogle Scholar
  33. 33.
    Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: A retrospective study on 860 patients from one institution. Ann Oncol. 2007;17:1228–33.CrossRefGoogle Scholar
  34. 34.
    Andre F, Mazouni C, Liedtke C, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat. 2007; DOI 10.1007/s10549-007-9594-8.Google Scholar
  35. 35.
    Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER1, HER2 and response: A study of preoperative chemotherapy. Ann Oncol. 2007, Epub 6 Nov.Google Scholar
  36. 36.
    Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 2004;22:4958–65.PubMedCrossRefGoogle Scholar
  37. 37.
    Evans TR, Yellowlees A, Foster E, Earl H et al. Phase III randomized trial of doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study. J Clin Oncol. 2005;23:2988–95.PubMedCrossRefGoogle Scholar
  38. 38.
    Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: Significant enhanced response with docetaxel. J Clin Oncol. 2002;20:1456–66PubMedCrossRefGoogle Scholar
  39. 39.
    Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathological complete remission in operable breast cancer when compared with paclitaxel one every 3 weeks. J Clin Oncol. 2005;23:5983–92.PubMedCrossRefGoogle Scholar
  40. 40.
    Frasci G, D’Aiuto G, Comella P, et al. A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: A phase II study. Ann Oncol. 2005;16:1268–75.PubMedCrossRefGoogle Scholar
  41. 41.
    Romieu G, Tubiana-Hulin M, Fumoleau P, et al. A multicenter randomized phase II study of 4 or 6 cycles of Adriamycin/taxol (paclitaxel) AT as neoadjuvant treatment of breast cancer. Ann Oncol. 2002;13(suppl):33–34.Google Scholar
  42. 42.
    Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoasduvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21:843–50.PubMedCrossRefGoogle Scholar
  43. 43.
    Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: Results of ABCSG-14. J Clin Oncol. 2007;25:2012–18.PubMedCrossRefGoogle Scholar
  44. 44.
    Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long term results from a prospective randomized trial. J Clin Oncol. 2004;22:2294–302.PubMedCrossRefGoogle Scholar
  45. 45.
    Abrial C, Mouret-Reynier M-A, Curé H, et al. Neoadjuvant endocrine therapy in breast cancer. Breast. 2006;15:9–19.PubMedCrossRefGoogle Scholar
  46. 46.
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12:1527–32.PubMedCrossRefGoogle Scholar
  47. 47.
    Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–16.PubMedGoogle Scholar
  48. 48.
    Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.PubMedCrossRefGoogle Scholar
  49. 49.
    Cataliotti L, Buzdar A, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer. The pre-operative “Arimidex” compared to tamoxifen (PROACT) trial. Cancer. 2006;106:2095–103.PubMedCrossRefGoogle Scholar
  50. 50.
    Semiglazov V, Kletsel A, Semiglazov V, et al. Exemestane versus tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1 T4N0M0). Proc ASCO. 2005;23 abs 530.Google Scholar
  51. 51.
    Paepke S, Jacobs VR, Paepke D, et al. Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: An update. Onkologie. 2006;29:210–17.PubMedCrossRefGoogle Scholar
  52. 52.
    Dixon JM, Jackson J, Renshaw L, Miller WR. Neoadjuvant tamoxifen and aromatase inhibitors: Comparisons and clinical outcomes. J Steroid Biochem Mol Biol. 2003;86:295–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen-receptor positive breast cancer. Cancer. 2007;110:244–54.PubMedCrossRefGoogle Scholar
  54. 54.
    Torrisi R, Bagnardi V, Pruneri G, et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007;97:802–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled open phase IIb study. J Clin Oncol. 2001;19:3506–15.Google Scholar
  56. 56.
    Bottini A, Berruti A, Brizzi MP, et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: A single-institution phase III trial. Endocrine Related Cancer. 2005;12:383–92.PubMedCrossRefGoogle Scholar
  57. 57.
    Albain KS. Adjuvant chemo-endocrine therapy for breast cancer: Combined or sequential? Breast. 2003;12:12.CrossRefGoogle Scholar
  58. 58.
    Torrisi R, Colleoni M, Veronesi P, et al. Primary therapy with ECF in combination with a GnRH analogue in premenopausal women with hormone receptor positive T2-T4 breast cancer. Breast. 2007;16:73–80.PubMedCrossRefGoogle Scholar
  59. 59.
    Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006;24:3623–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracile, doxorubicin and cyclophosphamide in breast cancer. J Clin Oncol. 2007;24:4236–44.CrossRefGoogle Scholar
  61. 61.
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRefGoogle Scholar
  62. 62.
    Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor positive breast cancer. J Clin Oncol. 2006;24:3726–34.PubMedCrossRefGoogle Scholar
  63. 63.
    Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7266–77.CrossRefGoogle Scholar
  64. 64.
    Sorlie T, Perou CM, Fan C, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther. 2006;5:2914–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85.PubMedCrossRefGoogle Scholar
  66. 66.
    Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22.PubMedCrossRefGoogle Scholar
  67. 67.
    Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.PubMedCrossRefGoogle Scholar
  68. 68.
    Gianni L, Semiglazov V, Manikhas GM, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl), 2007:532.Google Scholar
  69. 69.
    Polychronis A, Sinnett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 2005;6:383–91.PubMedCrossRefGoogle Scholar
  70. 70.
    Smith IE, Walsh GW, Skene A, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007;25:3816–22.PubMedCrossRefGoogle Scholar
  71. 71.
    Guarneri V, Frassoldati A, Ficarra, et al. Phase II randomized trial of preoperative epirubicin-paclitaxel ± gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Res Treat. 2007; DOI 10.1007/s10549-007-9688-3.Google Scholar
  72. 72.
    Spector NL, Blackwell K, Hurley J, et al. EGF 103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractorty inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. J Clin Oncol. 2006;24 (suppl):3S (abs 502).CrossRefGoogle Scholar
  73. 73.
    Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumour effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769–77.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Research Unit of Medical Senology, Department of MedicineEuropean Institute of OncologyMilanItaly

Personalised recommendations